Niraparib
Squamous Cell Carcinoma of the Cervix
Tarveda TherapeuticsSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Squamous Cell Carcinoma of the Cervix cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | BB |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Hycamtin National Cancer Institute (NCI) | Phase 2 | B |
PEGFILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
Rigosertib Traws Pharma, Inc. | Phase 2 | B |
View all 32 →
Same molecule, other indications
Niraparib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →